Literature DB >> 18670306

Prognostic significance of the number of lymph nodes removed at lobectomy in stage IA non-small cell lung cancer.

Sai-Hong Ignatius Ou1, Jason A Zell.   

Abstract

BACKGROUND: Lobectomy with mediastinal lymph node dissection is the standard of care in stage IA non-small cell lung cancer (NSCLC). We investigated whether the number of lymph nodes removed influences survival in stage IA NSCLC patients who underwent lobectomy.
METHODS: 2545 stage IA NSCLC patients in the California Cancer Registry who underwent lobectomy between 1999 and 2003 were analyzed. Cox proportional hazards regression was used to identify independent prognostic factors.
RESULTS: Increasing number of lymph nodes removed was associated with statistical significant improvements in overall survival (OS) (p = 0.0001) and lung cancer-specific survival (LCSS) (p = 0.0309) of stage IA NSCLC patients who underwent lobectomy. The number of lymph nodes removed remained an independent favorable prognostic factor for OS (ptrend = 0.0001) and LCSS (ptrend = 0.0095) even after adjustment for other independent prognostic factors including age, sex, histology, histologic grade, socioeconomic status, and marital status in the Cox proportional regression analyses. Removal of 11 to 15 lymph nodes conferred the lowest hazard ratio for death [versus none; hazard ratio = 0.52; 95% confidence interval: 0.36-0.75].
CONCLUSIONS: The number of lymph nodes removed in stage IA NSCLC patients who underwent lobectomy is an independent prognostic factor for OS and LCSS.

Entities:  

Mesh:

Year:  2008        PMID: 18670306     DOI: 10.1097/JTO.0b013e31817dfced

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  42 in total

1.  Response to editorial titled 'Intrapulmonary lymph node retrieval: unclear benefit for aggressive pathologic dissection'.

Authors:  Raymond U Osarogiagbon; Laura E Miller; Christopher G Wang; Robert A Ramirez
Journal:  Transl Lung Cancer Res       Date:  2013-04

Review 2.  Towards optimal pathologic staging of resectable non-small cell lung cancer.

Authors:  Raymond U Osarogiagbon; Gail E Darling
Journal:  Transl Lung Cancer Res       Date:  2013-10

3.  Improved lymph node staging in early-stage lung cancer in the national cancer database: commentary.

Authors:  Hisashi Saji; Koji Kojima; Haruhiko Nakamura
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

4.  Impact of lymph node management on resectable non-small cell lung cancer patients.

Authors:  Apichat Tantraworasin; Somcharoen Saeteng; Sophon Siwachat; Tawatchai Jiarawasupornchai; Nirush Lertprasertsuke; Sarawut Kongkarnka; Chidchanok Ruengorn; Jayanton Patumanond; Emanuela Taioli; Raja M Flores
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

5.  Predicting survival of patients with resectable non-small cell lung cancer: Beyond TNM.

Authors:  Raymond U Osarogiagbon
Journal:  J Thorac Dis       Date:  2012-04-01       Impact factor: 2.895

6.  Size and histologic characteristics of lymph node material retrieved from tissue discarded after routine pathologic examination of lung cancer resection specimens.

Authors:  Raymond U Osarogiagbon; Robert A Ramirez; Christopher G Wang; Laura E Miller; Laura McHugh; Courtney A Adair; Matthew P Smeltzer; Xinhua Yu; Allen Berry
Journal:  Ann Diagn Pathol       Date:  2014-02-10       Impact factor: 2.090

7.  Prognostic value of lymph node ratio in patients with pathological N1 non-small cell lung cancer: a systematic review with meta-analysis.

Authors:  Qian Li; Ping Zhan; Dongmei Yuan; Tangfeng Lv; Alexander Sasha Krupnick; Antonio Passaro; Alessandro Brunelli; Matthew P Smeltzer; Raymond U Osarogiagbon; Yong Song
Journal:  Transl Lung Cancer Res       Date:  2016-06

8.  Improving the pathologic evaluation of lung cancer resection specimens.

Authors:  Raymond U Osarogiagbon; Holly L Hilsenbeck; Elizabeth W Sales; Allen Berry; Robert W Jarrett; Christopher S Giampapa; Clara N Finch-Cruz; David Spencer
Journal:  Transl Lung Cancer Res       Date:  2015-08

9.  Quality Measures in Clinical Stage I Non-Small Cell Lung Cancer: Improved Performance Is Associated With Improved Survival.

Authors:  Pamela Samson; Traves Crabtree; Stephen Broderick; Daniel Kreisel; A Sasha Krupnick; G Alexander Patterson; Bryan Meyers; Varun Puri
Journal:  Ann Thorac Surg       Date:  2016-09-21       Impact factor: 4.330

10.  Socioeconomic risk factors for long-term mortality after pulmonary resection for lung cancer: an analysis of more than 90,000 patients from the National Cancer Data Base.

Authors:  Onkar V Khullar; Theresa Gillespie; Dana C Nickleach; Yuan Liu; Kristin Higgins; Suresh Ramalingam; Joseph Lipscomb; Felix G Fernandez
Journal:  J Am Coll Surg       Date:  2014-10-27       Impact factor: 6.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.